PRQR
ProQR Therapeutics N.V.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-23/100
Last price
1.65
▼ 0.02 (1.20%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.67
Day high
1.68
Day low
1.62
Volume
504.61K
Market cap
$232.85M
P/E (TTM)
—
52W range
1.33 – 3.10
Trailing performance
Returnvs SPY
1W
0.00%
-1.9%
1M
-20.29%
-21.4%
3M
-1.79%
-6.3%
6M
-2.94%
-21.1%
YTD
-18.32%
-32.6%
1Y
-32.65%
-49.1%
3Y
+26.92%
-55.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PRQR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
24.21M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 31, 26 | DE BOER DANIEL ANTON Chief Executive Officer |
BUY | 200.00K | $353.96K | Direct |
| Jul 17, 26 | FILIUS BART Director |
BUY | 150.00K | $257.93K | Direct |
| Jul 9, 26 | DE BOER DANIEL ANTON Chief Executive Officer |
BUY | 150.00K | $261.00K | Direct |
| Jul 7, 26 | DE BOER DANIEL ANTON Chief Executive Officer |
BUY | 150.00K | $238.50K | Direct |
| Jun 26, 26 | FILIUS BART Director |
BUY | 150.00K | $231.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DE BOER DANIEL ANTON |
Chief Executive Officer | 500.00K | Purchase |
FILIUS BART |
Director | 300.00K | Purchase |
Fundamentals
Market cap$232.85M
Enterprise value$131.04M
Revenue (TTM)$18.42M
Gross profit$18.42M
EBITDA$-41.90M
Net income$-42.04M
EPS (TTM)$-0.45
Free cash flow$-19.07M
Total cash$117.13M
Total debt$15.31M
Book value / share$0.63
Shares outstanding141.12M
Float91.44M
Short % of float2.24%
Dividend yield0.00%
Beta (5Y)0.20
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.49
PEG ratio—
Price / sales—
Price / book2.60
EV / revenue7.11
EV / EBITDA-3.13
Gross margin100.00%
Operating margin-100.72%
Profit margin-228.18%
Return on equity-57.40%
Return on assets-19.76%
Debt / equity19.27
Current ratio3.49
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $15.91M | $18.91M | $6.51M | $3.59M | -15.9% |
| Operating revenue | $15.91M | $18.91M | $6.51M | $3.59M | -15.9% |
| Research & development | $44.73M | $36.36M | $25.15M | $50.87M | +23.0% |
| Selling, general & admin | $15.06M | $13.66M | $16.24M | $18.65M | +10.2% |
| Total operating expense | $59.35M | $49.38M | $41.30M | $68.75M | +20.2% |
| Operating income | -$43.45M | -$30.47M | -$34.79M | -$65.16M | -42.6% |
| Net interest income | $1.40M | $2.17M | $1.39M | -$5.02M | -35.4% |
| Pre-tax income | -$42.16M | -$27.96M | -$27.81M | -$64.11M | -50.8% |
| Tax provision | $19.00K | -$197.00K | -$78.00K | $96.00K | +109.6% |
| Net income | -$42.18M | -$27.76M | -$28.12M | -$64.42M | -51.9% |
| Net income to common | -$42.18M | -$27.76M | -$28.12M | -$64.42M | -51.9% |
| Basic EPS | -0.40 | -0.32 | -0.35 | -0.90 | -25.0% |
| Diluted EPS | -0.40 | -0.32 | -0.35 | -0.90 | -25.0% |
| EBIT | -$41.24M | -$26.88M | -$26.61M | -$58.98M | -53.4% |
| EBITDA | -$38.53M | -$24.12M | -$24.10M | -$56.46M | -59.7% |
| Basic shares | 105.33M | 86.09M | 81.01M | 71.64M | +22.4% |
| Diluted shares | 105.33M | 86.09M | 81.01M | 71.64M | +22.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $92.41M | $149.41M | $118.92M | $94.78M | — | -38.1% |
| Cash & short-term investments | $92.41M | $149.41M | $118.92M | $94.78M | — | -38.1% |
| Accounts receivable | $3.36M | $0 | — | — | — | — |
| Total current assets | $100.13M | $153.84M | $120.99M | $154.46M | — | -34.9% |
| Property, plant & equipment | $12.63M | $14.11M | $16.90M | $16.24M | — | -10.5% |
| Total assets | $112.76M | $167.96M | $137.88M | $171.32M | — | -32.9% |
| Total current liabilities | $32.44M | $38.90M | $34.20M | $20.99M | — | -16.6% |
| Current debt | $4.87M | $4.58M | — | $2.50M | $4.77M | +6.3% |
| Long-term debt | — | — | $4.29M | $4.27M | $39.32M | — |
| Total debt | $15.96M | $17.22M | $19.73M | $21.97M | — | -7.3% |
| Total liabilities | $63.38M | $79.40M | $96.49M | $104.64M | — | -20.2% |
| Retained earnings | -$467.51M | -$427.16M | -$400.85M | -$379.11M | — | -9.4% |
| Shareholder equity | $49.37M | $88.56M | $41.39M | $67.06M | — | -44.2% |
| Working capital | $67.69M | $114.94M | $86.78M | $133.47M | — | -41.1% |
| Net tangible assets | $49.37M | $88.56M | $41.39M | $67.06M | — | -44.2% |
| Shares issued | 107.71M | 107.71M | 84.25M | 84.25M | — | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$42.18M | -$27.76M | -$27.73M | -$64.20M | -51.9% |
| Depreciation & amortisation | $2.70M | $2.76M | $2.51M | $2.52M | -2.1% |
| Stock-based compensation | $4.01M | $2.54M | $3.11M | $2.87M | +57.8% |
| Change in working capital | -$17.42M | -$13.26M | $48.96M | -$4.99M | -31.3% |
| Operating cash flow | -$52.79M | -$36.39M | $21.55M | -$68.51M | -45.1% |
| Capital expenditure | -$1.02M | -$1.42M | -$1.37M | -$708.00K | +28.1% |
| Investing cash flow | -$1.02M | -$4.07M | $4.28M | -$702.00K | +75.0% |
| Financing cash flow | -$1.84M | $70.28M | -$2.27M | -$30.89M | -102.6% |
| Free cash flow | -$53.81M | -$37.81M | $20.18M | -$69.22M | -42.3% |
| End cash position | $92.41M | $149.41M | $118.92M | $94.78M | -38.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $8.76M | $2.03M | $4.69M | $2.88M | $3.82M | — | +330.8% |
| Operating revenue | $8.76M | $2.03M | $4.69M | $2.88M | $3.82M | — | +330.8% |
| Research & development | $12.67M | $11.83M | $9.92M | $11.08M | $11.41M | — | +7.1% |
| Selling, general & admin | $4.91M | $3.85M | $3.89M | $3.12M | $4.82M | — | +27.6% |
| Total operating expense | $17.58M | $15.68M | $13.79M | $14.17M | $16.07M | — | +12.1% |
| Operating income | -$8.82M | -$13.65M | -$9.10M | -$11.28M | -$12.25M | — | +35.4% |
| Net interest income | $152.00K | $212.00K | $477.00K | $280.00K | $192.00K | — | -28.3% |
| Pre-tax income | -$8.70M | -$13.38M | -$8.92M | -$11.01M | -$12.16M | — | +35.0% |
| Tax provision | $25.00K | $0 | $1.00K | $0 | $18.00K | — | — |
| Net income | -$8.73M | -$13.38M | -$8.92M | -$11.01M | -$12.18M | — | +34.8% |
| Net income to common | -$8.73M | -$13.38M | -$8.92M | -$11.01M | -$12.18M | — | +34.8% |
| Basic EPS | — | -0.13 | — | -0.10 | -0.12 | -0.10 | — |
| Diluted EPS | — | -0.13 | — | -0.10 | -0.12 | -0.10 | — |
| EBIT | -$8.82M | -$13.65M | -$6.89M | -$11.28M | -$12.25M | — | +35.4% |
| EBITDA | -$8.12M | -$12.96M | -$6.21M | -$10.61M | -$11.57M | — | +37.4% |
| Basic shares | — | 105.36M | — | 105.34M | 105.34M | 105.30M | — |
| Diluted shares | — | 105.36M | — | 105.34M | 105.34M | 105.30M | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $117.13M | $81.09M | $92.41M | $106.88M | $119.77M | +44.4% |
| Cash & short-term investments | $117.13M | $81.09M | $92.41M | $106.88M | $119.77M | +44.4% |
| Accounts receivable | $3.91M | $4.40M | $3.36M | — | — | -11.3% |
| Total current assets | $121.63M | $86.98M | $100.13M | $111.33M | $124.28M | +39.8% |
| Property, plant & equipment | $11.92M | $12.05M | $12.63M | $13.02M | $13.26M | -1.1% |
| Total assets | $133.55M | $99.03M | $112.76M | $124.35M | $137.54M | +34.9% |
| Total current liabilities | $34.87M | $35.06M | $32.44M | $33.14M | $33.09M | -0.5% |
| Current debt | $5.02M | $4.95M | $4.87M | $4.80M | $4.73M | +1.5% |
| Total debt | $15.31M | $15.73M | $15.96M | $16.49M | $16.86M | -2.7% |
| Total liabilities | $54.08M | $61.44M | $63.38M | $67.28M | $70.55M | -12.0% |
| Retained earnings | -$487.41M | -$478.89M | -$467.51M | -$458.71M | -$447.77M | -1.8% |
| Shareholder equity | $79.48M | $37.60M | $49.37M | $57.07M | $66.98M | +111.4% |
| Working capital | $86.76M | $51.92M | $67.69M | $78.19M | $91.19M | +67.1% |
| Net tangible assets | $79.48M | $37.60M | $49.37M | $57.07M | $66.98M | +111.4% |
| Shares issued | 143.47M | 107.71M | 107.71M | 107.71M | 107.71M | +33.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$8.73M | -$13.38M | -$8.92M | -$11.01M | -$12.18M | +34.8% |
| Depreciation & amortisation | $707.00K | $694.00K | $679.00K | $671.00K | $675.00K | +1.9% |
| Stock-based compensation | $1.36M | $1.43M | $1.23M | $1.12M | $909.00K | -4.9% |
| Change in working capital | -$5.75M | $109.00K | -$6.44M | -$3.07M | -$1.18M | -5,378.9% |
| Operating cash flow | -$12.27M | -$11.14M | -$13.36M | -$12.23M | -$11.40M | -10.1% |
| Capital expenditure | -$291.00K | -$164.00K | -$526.00K | -$169.00K | -$101.00K | -77.4% |
| Investing cash flow | -$291.00K | -$164.00K | -$526.00K | -$169.00K | -$101.00K | -77.4% |
| Financing cash flow | $48.58M | -$304.00K | -$599.00K | -$444.00K | -$293.00K | +16,080.3% |
| Free cash flow | -$12.56M | -$11.31M | -$13.88M | -$12.40M | -$11.50M | -11.1% |
| End cash position | $117.13M | $81.09M | $92.41M | $106.88M | $119.77M | +44.4% |
Options analytics
Put / call volume
0.37
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
1.00
-39.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
27
Contracts, this expiry
Put volume
10
Contracts, this expiry
Heaviest call OI
1.00
0 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.18 | -0.09 | +49.5% |
| Mar 2026 | -0.18 | -0.15 | +14.6% |
| Dec 2025 | -0.12 | -0.09 | +21.2% |
| Sep 2025 | -0.17 | -0.12 | +29.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.11 | 2 | $4.93M | +46.7% |
| Next quarter | -0.14 | 2 | $4.87M | -10.9% |
| Current year | -0.46 | 2 | $20.48M | +8.3% |
| Next year | -0.47 | 2 | $18.36M | -10.3% |
Analyst targets & ownership
Mean target$7.78
High target$10.00
Low target$3.00
Implied upside371.38%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy1 / 8
Hold0
Sell / Strong sell0 / 0
Held by insiders17.16%
Held by institutions53.93%
Institutions holding76
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.66
-0.63% from price
SMA 20
1.77
-6.87% from price
SMA 50
1.93
-14.38% from price
SMA 100
1.78
-7.45% from price
SMA 200
1.74
-5.40% from price
EMA 12
1.71
-3.26% from price
EMA 26
1.80
-8.45% from price
EMA 50
1.84
-10.56% from price
RSI (14)
34.4
Neutral
MACD (12,26,9)
-0.10
Hist -0.01
ATR (14)
0.08
5.03% of price
Realised vol 30D
43.6%
Annualised
Bollinger upper
2.01
20, 2σ
Bollinger lower
1.54
20, 2σ
50 / 200 cross
Golden
1.93 vs 1.74
Trend bias
Below 200
-5.40%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.71
More volatile than market
Correlation to SPY
0.30
Largely independent
Realised vol 30D
43.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-55.1%
Peak to trough
Max drawdown 5Y
-93.4%
Peak to trough
ATR 14
0.08
5.03% of price
Beta (reported)
0.20
5Y monthly, from filing
Short interest
Shares short
2.41M
Prior 2.22M
Change vs prior
+8.1%
Shorts adding
% of float
2.24%
Normal
% of shares out
1.70%
Against total outstanding
Days to cover
2.7
Liquid
Float
91.44M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Oct 1, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 20, 26 | B of A Securities | INITIATED | — | Buy |
| Jun 29, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Jun 26, 26 | Jones Trading | MAINTAINED | Buy | Buy |
| Jun 26, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Apr 9, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Nov 4, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Aug 8, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jun 27, 25 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jun 27, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| May 13, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-23
Corporate Changes & Voting Matters
6-K · 2026-09-09
Corporate Changes & Voting Matters
6-K · 2026-08-13
Offering Registrations
F-3 · 2026-07-06
Corporate Changes & Voting Matters
6-K · 2026-06-25
Corporate Changes & Voting Matters
6-K · 2026-06-02
Corporate Changes & Voting Matters
6-K · 2026-05-12
Corporate Changes & Voting Matters
6-K · 2026-05-04
Headlines
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
MarketBeat · 5d ago
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
GlobeNewswire · 14d ago
ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment
MT Newswires · 28d ago
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
GlobeNewswire · 28d ago
ProQR to Participate in Upcoming Investor Conferences in September 2026
GlobeNewswire · 35d ago
ProQR: Q2 Earnings Snapshot
Associated Press · 54d ago
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Zacks · 54d ago
ProQR Announces Second Quarter 2026 Operating and Financial Results
GlobeNewswire · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.